Table 2 Progression-free survival (PFS) and best response (RECIST v1.1) to first subsequent treatment in evaluable patients

From: The efficacy of VEGFR TKI therapy after progression on immune combination therapy in metastatic renal cell carcinoma

 

Axitinib

(N = 14)

Pazopanib

(N = 7)

Cabozantinib

(N = 3)

Sunitinib

(N = 4)

Total cohort(N = 28)

Median PFS, months (CI 95%)

6.4a

(4.7–8.1)

5.6

(1.2–10.0)

NR

2.9

(0.0–7.6)

6.4a

(4.4–8.4)

Objective response rate (ORR)

29% (4)

43% (3)

33% (1)

0% (0)

29% (8)

Stable disease (SD)

64% (9)

29% (2)

66% (2)

50% (2)

54% (15)

Progressive disease (PD)

7% (1)

29% (2)

0% (0)

50% (2)

18% (5)

  1. NR not reached
  2. aOne patient who received axitinib in the third-line setting was excluded
Back to article page